tbuckley/cabot-search huggingface dataset:
AB0598 Significance of non criteria anti-phospholipid antibodies in the patients with systemie lupus erythrematosus associated with antiphospholipid syndrome
Authors: M. Dryglewska, A. Majdan, M. Majdan
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Systemic Lupus Erythematosus (SLE) is a chronic inflammatory autoimmune disease in which the uncontrolled activation of the immune system leads to overproduction of autoantibodies (Ab) with different mechanisms of action. Coexistence of anti-phospholipid antibodies (aPL) significantly increases the risk of thromboembolic complications and worsens the clinical course and prognosis of SLE. Objectives: The aim of study was to determine the relationship between the presence of non-criteria aPLs in SLE patients with criteria and non-criteria clinical symptoms of APS. <h3>Methods</h3> The study involved 70 (52-female and 18-male) patients treated in the Department of Rheumatology and Connective Tissue Diseases. All patients fulfilled the SLICC classification criteria of SLE. 46/70 pts fulfilled clinical and laboratory criteria of Antiphospholipid Syndrome (I group SLE/APS-46pts) and 24/70 pts (II group SLE/aPL (+) −24) -they had criteria antibodies but did not display clinical criteria symptoms of APS. In the whole study group the mean age was: 38,5±12,9 years (range 18–71), the duration of the disease was 8,3±6,5 years (range 0–37). The presence of Ab was detected in patients' serum using the commercially available tests: aPL-immunodot assay Anti-Phospholipid 10 Dot, for the qualitative detection of IgG or IgM antibodies. Statistical data analysis was performed using Statistica v13.0 <h3>Results</h3> <i>In the study group of 70 patients we detected the presence of the following aPLs:</i> a- cardiolipin IgM −33,7%, IgG −50%; a-phosphatidic acid IgM −17,5%, IgG −11,2%; a-phosphatidylcholine IgM and IgG −0; a-phosphatidylethanolamine IgM and IgG −0; a-phosphatidylglycerol IgM – 4,4%, IgG −10%; a-phosphatidylinositol IgM-11,2%, IgG-10%; a-phosphatidylserine IgM-31,2%, IgG-48,7%; a-annexin V IgM −20%, IgG −10%; a-b2-GP I IgM-33,7%, IgG-30%; a-prothrombin IgM −51,4%, IgG-30%. The following non-criteria clinical symptoms of APS were present: nephropathy in 27,1%, hypertension-41,1%, livedo reticularis 11,4%, convulsions/chorea-5,7%, thrombocytopenia- 20% of the study group. No statistically significant differences in the frequency of occurrence of individual non-criteria aPLs, as well as non-criteria clinical symptoms of APS have been found in the examined subgroups of SLE/SAPS and SLE/aPL (+) patients. <h3>Conclusions</h3> The prevalence of non-criteria aPLs in SLE and APS pts is similar to pts with SLE with criteria- aPL. Non-criteria clinical symptoms of APS occured with the same frequency in pts with SLE and APS and in SLE with criteria aPL. <h3>Disclosure of Interest</h3> None declared
Risk of cancer in 10 – 19 mm endoscopically detected colorectal lesions
Authors: Nasim Parsa, Prasanna Ponugoti, Heather Broadley, Jonathan Garcia, Douglas K. Rex
Journal: Endoscopy (2019)

Recent data indicate that the risk of cancer in colorectal lesions < 10 mm is lower than previously reported, possibly reflecting improved detection of flat, low-volume lesions with a low risk of cancer. Few studies have examined the prevalence of cancer in colorectal lesions 10 - 19 mm in size.We reviewed a prospectively collected database of all colorectal lesions removed at a single endoscopy center in order to identify lesions of 10 - 19 mm in size and review their histology. Lesions ≥ 20 mm were evaluated as a control group. We reviewed photographs of cancerous lesions to determine the frequency of endoscopic features of cancer.A total of 5093 lesions ≥ 10 mm were removed from 4020 patients (mean age 63.2 years, 34.4 % female). Among 3068 lesions 10 - 19 mm in size, 28 (0.9 %) had adenocarcinoma, including 1.2 % of conventional adenomas and 0.3 % of serrated class lesions. These rates were lower than the 6.9 % and 2.0 % rates of cancer found in conventional adenomatous lesions and serrated lesions ≥ 20 mm, respectively. Cancer was suggested by endoscopic features in 52.0 % of malignancies 10 - 19 mm in size compared with 79.2 % of lesions ≥ 20 mm.The prevalence of cancer in 10 - 19 mm colorectal lesions was much lower than previously reported. The cancer risk was higher in conventional adenomas than in serrated lesions. Cancer was endoscopically evident prior to resection in slightly more than half of colorectal lesions 10 - 19 mm in size.
AB1156 Dress (DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS): looks may be deceptive!
Authors: R. Mistry, A. Jain, S. Ravi, D. Misra, N. Krishnani, V. Aggarwal
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Drug reaction with eosinophilia and systemic symptoms(DRESS) is a rare, potentially life threatening multisystem disorder with fever, skin eruptions, lymphadenopathy, eosinophilia and systemic involvement most commonly after a drug exposure. These cases may mimic various rheumatological conditions. We report a series of 14 cases of DRESS who presented to Rheumatology Clinic as suspected connective tissue disease or sepsis in Northern India. <h3>Objectives</h3> To highlight DRESS as a common mimic of common rheumatologic conditions and sepsis and report its etiology, characteristics, treatment and prognosis <h3>Methods</h3> We manually searched the inpatient records of Immunology Department in SGPGI 2007–18 for the cases discharged with a diagnosis of possible/probable/definite DRESS. The records of the patients with probable and definite DRESS according to regiSCAR critera<sup>1</sup> were reviewed. <h3>Results</h3> All the 14 patients fulfilled clinical criteria for diagnosis (4 probable, 10 definite). The age of patients ranged from 9–53 years with majority in their 3rd decade. Majority of the patients were referred to us when their counts were rising in the setting of fever and skin rashes with a suspicion of rheumatic disease/sepsis. The clinical and laboratory features of these patients are as follows (table 1): TLC: Total Leucocyte Count, AEC: Absolute Eosinophil Count, ED: Exfoliative dermatitis, F: facial oedema, M: maculopapular rash, L: Liver, K: Kidney, P: Lung, G: GI, SSZ: Sulphasalazine, HRZE: Isoniazid, Rifampicin, Pyrazinamide, Ethambutol, FU: Follow up All the patients were treated with oral steroids showing signs of clinical improvement within 4–5 days. Rashes and leucocyte count were first to respond. Transaminitis responded within a week. Mean Followup is 9.3 months. They were gradually tapered off steroids over next 3–4 months except for two patient who were lost to follow up. <h3>Conclusions</h3> – Skin rash, arthritis, multi-organ failure of DRESS closely mimic rheumatologic disorders or sepsis (especially with rising TLC) - As early diagnosis is imperative for successful outcome, low threshold of suspicion is necessary. <h3>Reference</h3> [1] Kardaun SH, Sidoroff A, Valeyrie-Allanore L, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: Does a DRESS syndrome really exist?Br J Dermatol2007; 156:609. <h3>Disclosure of Interest</h3> None declared
The Hail Mary Pass
Authors: Kristi L. Kirschner
Journal: JAMA Cardiology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
THU0464 Increased frequency of obstructive sleep apnea syndrome in behcet’s syndrome patients with vena cava superior thrombosis
Authors: A. Gokturk, S.N. Esatoglu, Y. Ozguler, E. Atahan, B. Musellim, V. Hamuryudan, H. Yazici, E. Seyahi
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Superior vena cava syndrome (SVCS), is a medical emergency and can also be seen in Behçet's syndrome (BS). Contrary to the severe outcome seen in malign conditions, SVCS in BS usually has a benign course, complicated rarely by hemoptysis, pleural effusion, and a chylothorax. We had noted that BS patients with SVCS frequently complained of sleep disturbances, snoring and sleep apnea, suggesting an obstructive sleep apnea (OSA) disorder. <h3>Objectives</h3> We formally surveyed the degree of risk for OSA among BS patients with SVCS and suitable controls using the Berlin questionnaire, a screening questionnaire for OSA with a high sensitivity and modest specificity.<sup>1</sup> <h3>Methods</h3> Because of the lower frequency of female patients with VCSS (n=2), only males were included. We studied 28 BS patients with SVCS (Group 1), 80 BS patients with vascular involvement without a SVCS (Group 2), and 59 BS patients with no vascular involvement (Group 3). Also, 80 apparently healthy individuals (Group 4) of similar age and gender to BS patients were studied. Polysomnography was performed in patients at high risk for OSA according to the Berlin questionnaire. <h3>Results</h3> There were no differences regarding demographic characteristics, disease duration, and variables associated with OSA among the groups (table 1). The Berlin questionnaire categorised 57.1% (16/28) of the BS patients with SVCS (Group 1) as having a high risk for OSA and this was significantly higher compared to that found in the control groups. The frequency of those at high risk for OSA was 15%, 8.5%, 11.3% in Group 2, 3 and 4, respectively (p&gt;0.05). Until now, polysomnography was performed in 12 subjects (5 patients with SVCS, 1 patient with vascular involvement without a SVCS and 6 healthy controls). OSA was detected in 3/5 patients with SVCS and 1/1 patient with vascular involvement without a SVCS and 4/6 healthy controls. <h3>Conclusions</h3> This study shows that BS patients with a history of VCSS are at high risk of OSA. This is probably due to the external pressure of the significant venous collaterals on the upper airways. <h3>Reference</h3> [1] Netzer NC, Stoohs RA, Netzer CM, Clark K, Strohl KP. Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. Ann Intern Med1999Oct 5;131(7):485–91. <h3>Disclosure of Interest</h3> None declared
AB0467 Sustained clinical response in refractory rheumatoid arthritis patients with a low-dose rituximab retreatment regimen
Authors: S.D.L.C. Rodriguez García, R. Castellanos-Moreira, M.V. Hernandez-Miguel, A. Cuervo, V. Ruiz-Esquide, J. Ramirez, O. Camacho, J.D. Cañete, J. Gomez Puerta, R. Sanmartí
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The standard dose of rituximab (RTX) in rheumatoid arthritis (RA) is two intravenous (iv) 1 g infusions, separated by two weeks. Recently, the efficacy of a low-dose of RTX for retreatment in RA patients has been reported.<sup>1</sup> <h3>Objectives</h3> Our aim was to assess the long-term sustained effectiveness of a low-dose of RTX in daily clinical practice. <h3>Methods</h3> Observational retrospective study including all RA patients treated on a tertiary hospital who had received at least one cycle of RTX, at the standard dose, between June 2006 and May 2017. We selected those patients who achieved a good or moderate EULAR response and thereafter were down-titrated to a low-dose regimen (1 g). Variables analysed: age, sex, disease duration, presence of ACPA (antiCCP2) and rheumatoid factor (RF), glucocorticoid (GC) and conventional synthetic DMARD (csDMARD) use and dosage before and after RTX treatment, number of biologic DMARD (bDMARD) used prior to initiating RTX. Disease activity was measured using DAS28 index (prior to first RTX infusion, at low-dose regimen initiation and at last follow-up visit). <h3>Results</h3> 53 patients received, at least, one cycle of 2 g RTX, 70% achieved a good or moderate EULAR response and were stepped-down to a low dose re-treatment regimen. Baseline characteristics of patients receiving low-dose RTX were: mean age 56.4±10.9 years; 13.5% male, mean disease duration 12.7±9.8 years, 91.9% RF +and 97.3% ACPA +; mean DAS28 prior to RTX initiation 5,79±1,17. 73% of patients had received other bDMARD before RTX, 48% 2 or more. 92% were on cs-DMARDs, 51.4% methotrexate (MTX) and 37.8% leflunomide (LEF) and 86.5% were receiving concomitant GC (median dose 10 mg, P<sub>25–75</sub> 5–10 mg). 73% of subjects received only one standard cycle before RTX dose reduction. Mean DAS28 decreased significantly between the first visit on 1 g RTX vs the last follow-up visit (4.08 vs 3.04; p&lt;0.0001). Additionally, 11 patients (8 MTX, 3 LEF) were able to reduce csDMARD dosage, 56.3% of patients receiving GC at the initiation of low-dose retreatment were able to reduce the dose (median 10 mg vs 5 mg; p&lt;0.0001), and 28% discontinued GC therapy. After a mean follow-up of 3±1.8 years, RTX was withdrawn in 10 patients: 8 due to adverse events (recurrent infections in 4) and 2 cases due to loss of efficacy. <h3>Conclusions</h3> A sustained clinical response was observed with the 1 gr retreatment of RTX after a long-term follow-up period. <h3>Reference</h3> [1] Mariette X, et al. Ann Rheum Dis2014;73:1508–14. <h3>Disclosure of Interest</h3> None declared
AB0118 Oral contraceptives and the risk of developing rheumatoid arthritis: results from the malaysian epidemiological investigation of rheumatoid arthritis case-control study
Authors: C.L. Too, A.F. Nurul Aain, L.K. Tan, I.S. Lau, M.L. Nor Asiah, S. Salsabil, H. Heselynn, S. Nor Shuhaila, S. Wahinuddin, S.C. Gun, B. Eashwary, M.S. Mohd Shahrir, M. Ainon, R. Azmillah, O. Muhaini, B. Camilla, L. Padyukov, L. Alfredsson, L. Klareskog, M.L. Shahnaz
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Hormonal and reproductive factors are implicated in the etiology of rheumatoid arthritis (RA). The association between oral contraceptive (OC) use and the risk of RA has been reported, but the findings are inconsistent across different populations. <h3>Objectives</h3> We investigated the association between OC use and risk of RA stratified by anti-citrullinated peptide antibody (ACPA) status in the Malaysian female population. <h3>Methods</h3> Data from the Malaysian Epidemiological Investigation of rheumatoid Arthritis (MyEIRA) population-based case control study involving 902 female early RA and 906 age and residential area-matched female controls were analysed. OC use data was assessed through a questionnaire. Never users of OC were compared with ever users of OC to estimate the risk of developing ACPA-positive and ACPA negative RA. The odds ratio (OR) with 95% confidence interval (CI) was calculated. <h3>Results</h3> In this study, a total of 28.4% (n=254) RA cases and 34.2% (n=310) controls had reported as ever OC users. Compared with never users, ever OC users had a decreased risk of developing RA in the Malaysian population particularly in ACPA-negative RA (OR 0.68, 95% CI 0.51–0.90, p&lt;0.001). No significant association was observed between ever OC users and ACPA-positive RA (OR 0.80, 95% CI 0.64–1.01). Further stratification analysis by duration of OC use (less than or more than 7 years versus never OC use) demonstrated significant decreased risk of developing ACPA-positive RA (OR 0.66, 95% CI 0.51–0.86, p&lt;0.01) and ACPA-negative RA (OR 0.57, 95% CI 0.41–0.80, p&lt;0.001), respectively. <h3>Conclusions</h3> Oral contraceptives decreased the risk of RA, particularly ACPA-negative RA in the Malaysian population. A long duration of OC use was however decreased the risk in both ACPA-positive and ACPA-negative RA subsets. <h3>References</h3> [1] Orellano C, Saevardottir S, Klareskog L, Karlson EW, Alfredsson L, Bengtsson C. Oral contraceptives, breastfeeding and the risk of developing rheumatoid arthritis: results from the Swedish Epidemiological Investigation of Rheumatoid Arthritis study. Ann Rheum Dis. 2017;76:1845–1852. [2] Adab P, Jiang CQ, Rankin E, Tsang YW, Lam TH, Barlow J, Thomas GN, Zhang WS and Cheng KK. Breastfeeding practice, oral contraceptive use and risk of rheumatoid arthritis among Chinese women: the Guangzhou Biobank Cohort Study. Rheumatology (Oxford)2014;53(5):860–6. <h3>Disclosure of Interest</h3> None declared
Complete Remissions Post Infusion of Multiple Tumor Antigen Specific T Cells for the Treatment of High Risk Leukemia and Lymphoma Patients after HCT
Authors: Kirsten M. Williams, Patrick Hanley, Melanie Grant, Maria Fernanda Fortiz, Maja Stanojevic, Mimi Ismail, Fahmida Hoq, Maria Martin Manso, Jamie Hoover, Robert Ulrey, Ella Kathy Mintz, Anna Namata, Elizabeth Williams, Shuroug Albihani, Michael Keller, Conrad Russell Young Cruz, Haili Lang, Austin John Barrett, Stephen Gottschalk, Hao Liu, Shannon R. McCurdy, Richard J. Jones, Catherine M. Bollard
Journal: Blood (2017)
Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve &amp; Relapsed (Rel)/Refractory (Ref) Patients
Authors: Shyamala C. Navada, Guillermo Garcia-Manero, Ehab L. Atallah, M. Nabeel Rajeh, Jamile M. Shammo, Elizabeth A. Griffiths, Samer K. Khaled, Shaker R. Dakhil, David E. Young, Rosalie Odchimar-Reissig, Naveen Pemmaraju, Yesid Alvarado, Maro N. Ohanian, Rosmy B. John, Patrick S. Zbyszewski, Manoj Maniar, Michael E. Petrone, Steven M. Fruchtman, Lewis R. Silverman
Journal: Blood (2018)
Abstract 20602: First Trimester PM2.5 Exposure Contributes to Adult Cardiac Dysfunction in Offspring
Authors: Vineeta Tanwar, Matthew W Gorr, Dane J Youtz, Loren E Wold
Journal: Circulation (2017)

Introduction: PM2.5 exposure during entire in utero period is associated with adverse cardiovascular outcomes at adulthood. Hypothesis: We hypothesize that PM2.5 exposure can exert different cardia...
A EAACI drug allergy interest group survey on how European allergy specialists deal with β‐lactam allergy
Authors: Maria Jose Torres, Gulfem Elif Celik, Paul Whitaker, Marina Atanaskovic‐Markovic, Annick Barbaud, Andreas Bircher, Miguel Blanca, Knut Brockow, Jean‐Christoph Caubet, Josefina Rodrigues Cernadas, Anca Chiriac, Pascal Demoly, Lene Heise Garvey, Hans F. Merk, Holger Mosbech, Alla Nakonechna, Antonino Romano
Journal: Allergy (2019)

An accurate diagnosis of β-lactam (BL) allergy can reduce patient morbidity and mortality. Our aim was to investigate the availability of BL reagents, their use and test procedures in different parts of Europe, as well as any differences in the diagnostic workups for evaluating subjects with BL hypersensitivity. A survey was emailed to all members of the EAACI Drug Allergy Interest Group (DAIG) between February and April 2016, and the questionnaire was meant to study the management of suspected BL hypersensitivity. The questionnaire was emailed to 82 DAIG centres and answered by 57. Amoxicillin alone or combined to clavulanic acid were the most commonly involved BL except in the Danish centre, where penicillin V was the most frequently suspected BL. All centres performed an allergy workup in subjects with histories of hypersensitivity to BL: 53 centres (93%) followed DAIG guidelines, two national guidelines and two local guidelines. However, there were deviations from DAIG recommendations concerning allergy tests, especially drug provocation tests. A significant heterogeneity exists in current practice not only among countries, but also among centres within the same country. This suggests the need to re-evaluate, update and standardize protocols on the management of patients with suspected BL allergy.
Methyldopa for Treatment of Hypertension
Authors: B L GILMORE, E D FREIS
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
HIV Viral Load and Transmissibility of HIV Infection
Authors: Robert W. Eisinger, Carl W. Dieffenbach, Anthony S. Fauci
Journal: JAMA (2019)

In this Viewpoint, Fauci and colleagues from NIAID review the evidence underlying the 2016 Prevention Access Campaign's "Undetectable = Untransmittable (U = U)" HIV public health initiative, arguing that the science now supports elimination of the stigma associated with HIV infection.
Abstract 19750: Cardiac Biomarkers and MicroRNAs as Predictors of Cardiovascular Events in Asymptomatic Individuals
Authors: Anna P Pilbrow, Adam S Runesson, Mikael A Sommer, Christopher M Frampton, Christopher J Pemberton, Richard W Troughton, A M Richards, Vicky A Cameron
Journal: Circulation (2017)

Background: Circulating biomarkers may improve prediction of cardiovascular (CV) events in the general population, beyond traditional risk factors. Aim: To investigate if circulating N-terminal pro-brain natriuretic peptide (NT-proBNP), high sensitivity troponin I (hsTNI) and microRNAs (miRNAs) could improve risk prediction among asymptomatic individuals. Methods: Participants with no history of CV disease were recruited from the general population (n=2940, age 64±11 years, 67% male). Fatal/non-fatal CV events (myocardial infarction (MI), unstable angina, ischemic stroke, transient ischemic attack, heart failure) were recorded over a median 8 years follow-up. Associations between known risk factors (age, gender, ethnicity, cigarette smoking, body mass index, systolic blood pressure, diabetes, family history of MI, blood pressure medications), plasma NT-proBNP, hsTNI and CV events were tested with Cox regression and log-rank tests. In an exploratory substudy, associations between CV events and plasma level...
JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis
Authors: Jennifer R. Lynch, Basit Salik, Patrick Connerty, Binje Vick, Halina Leung, Aster Pijning, Irmela Jeremias, Karsten Spiekermann, Toby Trahair, Tao Liu, Michelle Haber, Murray D. Norris, Andrew J. Woo, Philip Hogg, Jianlong Wang, Jenny Y. Wang
Journal: Leukemia (2019)